A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Summary

The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).

Timeline

Start

2024-10-21

Primary completion

2026-02-06

Completion

2026-06-03

Outcome

Met primary endpoint

release “BE BOLD represents the fourth head-to-head study demonstrating bimekizumab superiority” ucb.com ↗

release “Bimekizumab met the primary endpoint for BE BOLD of superiority in ACR50 at Week 16” ucb.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimekizumab	Monoclonal antibody	—	—
Comparator	Risankizumab	Monoclonal antibody	—	—

Indications